SE9701956D0 - New composition of matter - Google Patents

New composition of matter

Info

Publication number
SE9701956D0
SE9701956D0 SE9701956A SE9701956A SE9701956D0 SE 9701956 D0 SE9701956 D0 SE 9701956D0 SE 9701956 A SE9701956 A SE 9701956A SE 9701956 A SE9701956 A SE 9701956A SE 9701956 D0 SE9701956 D0 SE 9701956D0
Authority
SE
Sweden
Prior art keywords
treatment
particles
matter
new composition
budesonide
Prior art date
Application number
SE9701956A
Other languages
English (en)
Swedish (sv)
Inventor
Mikael Bisrat
Saeed Moshashaee
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9701956A priority Critical patent/SE9701956D0/xx
Publication of SE9701956D0 publication Critical patent/SE9701956D0/xx
Priority to DK98924697T priority patent/DK1005328T3/da
Priority to AU76800/98A priority patent/AU734763B2/en
Priority to TR1999/02880T priority patent/TR199902880T2/xx
Priority to SK1587-99A priority patent/SK158799A3/sk
Priority to JP55028498A priority patent/JP2001525850A/ja
Priority to PCT/SE1998/000908 priority patent/WO1998052544A1/en
Priority to IL13309898A priority patent/IL133098A/xx
Priority to NZ500852A priority patent/NZ500852A/en
Priority to ES98924697T priority patent/ES2205496T3/es
Priority to IDW991396A priority patent/ID24332A/id
Priority to BR9808812-2A priority patent/BR9808812A/pt
Priority to DE69816997T priority patent/DE69816997T2/de
Priority to HU0002212A priority patent/HUP0002212A3/hu
Priority to EEP199900533A priority patent/EE03850B1/et
Priority to PT98924697T priority patent/PT1005328E/pt
Priority to TW087107532A priority patent/TW518236B/zh
Priority to ZA984127A priority patent/ZA984127B/xx
Priority to PL98336902A priority patent/PL336902A1/xx
Priority to KR10-1999-7010785A priority patent/KR100514971B1/ko
Priority to US09/091,453 priority patent/US6346523B1/en
Priority to CNB988053381A priority patent/CN1146406C/zh
Priority to CA002290538A priority patent/CA2290538C/en
Priority to AT98924697T priority patent/ATE246492T1/de
Priority to EP98924697A priority patent/EP1005328B1/en
Priority to ARP980102400A priority patent/AR015820A1/es
Priority to NO19995540A priority patent/NO995540L/no
Priority to IS5254A priority patent/IS5254A/is
Priority to US09/992,940 priority patent/US6468994B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SE9701956A 1997-05-23 1997-05-23 New composition of matter SE9701956D0 (sv)

Priority Applications (29)

Application Number Priority Date Filing Date Title
SE9701956A SE9701956D0 (sv) 1997-05-23 1997-05-23 New composition of matter
EP98924697A EP1005328B1 (en) 1997-05-23 1998-05-15 Composition comprising finely divided, crystalline particles of budesonide
DE69816997T DE69816997T2 (de) 1997-05-23 1998-05-15 Mittel, die fein verteilte, kristalline budenosid-partikel enthalten
EEP199900533A EE03850B1 (et) 1997-05-23 1998-05-15 Budesoniidi peenestatud kristallilisi osakesi sisaldav ravimvorm
TR1999/02880T TR199902880T2 (xx) 1997-05-23 1998-05-15 �nce par�alanm�� kristal budesonid par�ac�klar� i�eren kompozisyon
SK1587-99A SK158799A3 (en) 1997-05-23 1998-05-15 Composition comprising finely divided, crystalline particles of budesonide
JP55028498A JP2001525850A (ja) 1997-05-23 1998-05-15 ブデソニドの粉砕した結晶粒子を含む組成物
PCT/SE1998/000908 WO1998052544A1 (en) 1997-05-23 1998-05-15 Composition comprising finely divided, crystalline particles of budesonide
IL13309898A IL133098A (en) 1997-05-23 1998-05-15 Composition comprising finely divided crystalline particles of budesonide
NZ500852A NZ500852A (en) 1997-05-23 1998-05-15 Composition comprising finely divided, crystalline particles of budesonide characterised in that they are smooth and have a BET value from 1-4.5m2/g
ES98924697T ES2205496T3 (es) 1997-05-23 1998-05-15 Composicion que comprende particulas cristalinas de budesonida finamente divididas.
IDW991396A ID24332A (id) 1997-05-23 1998-05-15 Komposisi yang mengandung partikel budesonida berbentuk kristal yang halus
BR9808812-2A BR9808812A (pt) 1997-05-23 1998-05-15 Composição compreendendo partìculas cristalinas, finamente divididas de budesonida
DK98924697T DK1005328T3 (da) 1997-05-23 1998-05-15 Sammensætning omfattende findelte krystallinske partikler af budesonid
HU0002212A HUP0002212A3 (en) 1997-05-23 1998-05-15 Composition comprising finely divided, crystalline particles of budesonide and preparation thereof
AU76800/98A AU734763B2 (en) 1997-05-23 1998-05-15 Composition comprising finely divided, crystalline particles of budesonide
PT98924697T PT1005328E (pt) 1997-05-23 1998-05-15 Composicao compreendendo particulas de budesonido cristalinas finamente divididas
TW087107532A TW518236B (en) 1997-05-23 1998-05-15 Finely divided, substantially crystalline particles of budesonide, pharmaceutical composition comprising them and the preparation thereof
ZA984127A ZA984127B (en) 1997-05-23 1998-05-15 New composition of matter
PL98336902A PL336902A1 (en) 1997-05-23 1998-05-15 Composition containing finely comminuted crystalline particles of budesonide
KR10-1999-7010785A KR100514971B1 (ko) 1997-05-23 1998-05-15 부데소니드의 미분 결정질 입자를 함유하는 조성물
US09/091,453 US6346523B1 (en) 1997-05-23 1998-05-15 Budesonide particles and pharmaceutical compositions containing them
CNB988053381A CN1146406C (zh) 1997-05-23 1998-05-15 包含布地缩松细碎结晶颗粒的组合物
CA002290538A CA2290538C (en) 1997-05-23 1998-05-15 Composition comprising finely divided, crystalline particles of budesonide
AT98924697T ATE246492T1 (de) 1997-05-23 1998-05-15 Mittel, die fein verteilte, kristalline budenosid-partikel enthalten
ARP980102400A AR015820A1 (es) 1997-05-23 1998-05-22 Particulas de budesonida, composicion farmaceutica, uso de dichas particulas para la fabricacion de medicamentos, metodo para el tratamiento de untrastorno respiratorio y proceso para la preparacion de las particulas
NO19995540A NO995540L (no) 1997-05-23 1999-11-12 Preparat omfattende findelte, krystallinske partikler av budesonid
IS5254A IS5254A (is) 1997-05-23 1999-11-18 Samsetning sem inniheldur fíngerðar, kristallaðaragnir af búdesóníð
US09/992,940 US6468994B2 (en) 1997-05-23 2001-11-06 Budesonide particles and pharmaceutical compositions containing them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9701956A SE9701956D0 (sv) 1997-05-23 1997-05-23 New composition of matter

Publications (1)

Publication Number Publication Date
SE9701956D0 true SE9701956D0 (sv) 1997-05-23

Family

ID=20407079

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9701956A SE9701956D0 (sv) 1997-05-23 1997-05-23 New composition of matter

Country Status (28)

Country Link
US (2) US6346523B1 (et)
EP (1) EP1005328B1 (et)
JP (1) JP2001525850A (et)
KR (1) KR100514971B1 (et)
CN (1) CN1146406C (et)
AR (1) AR015820A1 (et)
AT (1) ATE246492T1 (et)
AU (1) AU734763B2 (et)
BR (1) BR9808812A (et)
CA (1) CA2290538C (et)
DE (1) DE69816997T2 (et)
DK (1) DK1005328T3 (et)
EE (1) EE03850B1 (et)
ES (1) ES2205496T3 (et)
HU (1) HUP0002212A3 (et)
ID (1) ID24332A (et)
IL (1) IL133098A (et)
IS (1) IS5254A (et)
NO (1) NO995540L (et)
NZ (1) NZ500852A (et)
PL (1) PL336902A1 (et)
PT (1) PT1005328E (et)
SE (1) SE9701956D0 (et)
SK (1) SK158799A3 (et)
TR (1) TR199902880T2 (et)
TW (1) TW518236B (et)
WO (1) WO1998052544A1 (et)
ZA (1) ZA984127B (et)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4990696A (en) * 1995-02-24 1996-09-11 Nanosystems L.L.C. Aerosols containing nanoparticle dispersions
AU3465901A (en) * 2000-03-03 2001-09-17 Boehringer Ingelheim Pharma Material processing by repeated solvent expansion-contraction
EP1354581A4 (en) * 2000-12-26 2007-07-04 Takeda Pharmaceutical POROUS SUBSTANCE AND METHOD FOR THE PRODUCTION THEREOF
GB0106403D0 (en) * 2001-03-15 2001-05-02 Pharmaceutical Profiles Labelling of dry powder formulations for inhalation
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
US6746635B2 (en) 2001-08-08 2004-06-08 Brown University Research Foundation Methods for micronization of hydrophobic drugs
IL160931A0 (en) * 2001-10-10 2004-08-31 Boehringer Ingelheim Pharma Powder processing with pressurized gaseous fluids
US20030129242A1 (en) * 2002-01-04 2003-07-10 Bosch H. William Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
GB0216562D0 (en) * 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
WO2004105809A1 (en) 2003-05-22 2004-12-09 Elan Pharma International Ltd. Sterilization of dispersions of nanoparticulate active agents with gamma radiation
TWI359675B (en) 2003-07-10 2012-03-11 Dey L P Bronchodilating β-agonist compositions
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
US20070020298A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether gamma-cyclodextrin and corticosteroid
US20070020196A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid prepared from a unit dose suspension
ATE446581T1 (de) * 2004-03-12 2009-11-15 Trinity College Dublin Magnetoresistives medium
JP2008533055A (ja) * 2005-03-18 2008-08-21 ナノマテリアルズ テクノロジー ピーティーイー リミテッド 吸入剤
US8475845B2 (en) 2005-07-15 2013-07-02 Map Pharmaceuticals, Inc. Method of particle formation
EP1782839A1 (en) 2005-11-03 2007-05-09 Genetic S.p.A. Sterilization process of Glucocorticosteroid by supercritical CO2
US20070160542A1 (en) * 2005-12-20 2007-07-12 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070178049A1 (en) * 2005-12-20 2007-08-02 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
US20070249572A1 (en) * 2005-12-20 2007-10-25 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070185066A1 (en) * 2005-12-20 2007-08-09 Verus Pharmaceuticals, Inc. Systems and methods for the delivery of corticosteroids
US20070197486A1 (en) * 2005-12-20 2007-08-23 Verus Pharmaceuticals, Inc. Methods and systems for the delivery of corticosteroids
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
EP1993598A2 (en) * 2006-02-15 2008-11-26 Tika Läkemedel AB Methods of manufacturing corticosteroid solutions
ES2691033T3 (es) 2007-02-11 2018-11-23 Map Pharmaceuticals Inc. Método de administración terapéutica de DHE para activar el alivio rápido de la migraña a la vez que se reduce al mínimo el perfil de los efectos secundarios
US20100294986A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Supercritical fluid facilitated particle formation in microfluidic systems
US20100298602A1 (en) * 2009-05-19 2010-11-25 Massachusetts Institute Of Technology Systems and methods for microfluidic crystallization
AU2011305566A1 (en) * 2010-09-22 2013-05-02 Map Pharmaceuticals, Inc. Aerosol composition for administering drugs
CN102975731B (zh) * 2012-04-24 2015-08-12 南车南京浦镇车辆有限公司 轨道车辆司机室骨架与车体的安装结构
WO2021219230A1 (en) 2020-04-30 2021-11-04 Paolo Fiorina Antiviral treatment
KR102567655B1 (ko) 2020-11-13 2023-08-17 주식회사 비츠로이엠 진공커패시터 및 진공커패시터 제조 방법
KR20230072023A (ko) 2021-11-17 2023-05-24 주식회사 비츠로이엠 가변형 진공 커패시터의 나선형 전극 위치 결정구조
KR20230072022A (ko) 2021-11-17 2023-05-24 주식회사 비츠로이엠 가변형 진공 커패시터

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1282405C (en) 1984-05-21 1991-04-02 Michael R. Violante Method for making uniformly sized particles from water-insoluble organic compounds
HU209603B (en) 1988-10-05 1994-09-28 Upjohn Co Process for production of solid powders in finalydivided microcristallin form
GB9001635D0 (en) 1990-01-24 1990-03-21 Ganderton David Aerosol carriers
JP3282731B2 (ja) 1990-06-15 2002-05-20 メルク エンド カムパニー インコーポレーテッド 結晶の構造および大きさを改良する結晶化方法
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
US5874063A (en) * 1991-04-11 1999-02-23 Astra Aktiebolag Pharmaceutical formulation
WO1993011773A1 (en) * 1991-12-18 1993-06-24 Aktiebolaget Astra New combination of formoterol and budesonide
GB9313642D0 (en) 1993-07-01 1993-08-18 Glaxo Group Ltd Method and apparatus for the formation of particles
SE9501384D0 (sv) 1995-04-13 1995-04-13 Astra Ab Process for the preparation of respirable particles

Also Published As

Publication number Publication date
EP1005328B1 (en) 2003-08-06
CN1257424A (zh) 2000-06-21
AR015820A1 (es) 2001-05-30
CA2290538A1 (en) 1998-11-26
ES2205496T3 (es) 2004-05-01
DE69816997T2 (de) 2004-07-22
KR20010012821A (ko) 2001-02-26
ATE246492T1 (de) 2003-08-15
TR199902880T2 (xx) 2000-02-21
EE03850B1 (et) 2002-10-15
NO995540D0 (no) 1999-11-12
SK158799A3 (en) 2000-05-16
EP1005328A1 (en) 2000-06-07
EE9900533A (et) 2000-06-15
KR100514971B1 (ko) 2005-09-15
HUP0002212A2 (hu) 2000-12-28
DK1005328T3 (da) 2003-11-17
AU734763B2 (en) 2001-06-21
WO1998052544A1 (en) 1998-11-26
DE69816997D1 (de) 2003-09-11
HUP0002212A3 (en) 2001-04-28
PL336902A1 (en) 2000-07-17
US20020037257A1 (en) 2002-03-28
PT1005328E (pt) 2003-11-28
NO995540L (no) 1999-11-12
NZ500852A (en) 2001-07-27
US6468994B2 (en) 2002-10-22
BR9808812A (pt) 2000-07-18
IS5254A (is) 1999-11-18
AU7680098A (en) 1998-12-11
US6346523B1 (en) 2002-02-12
CN1146406C (zh) 2004-04-21
JP2001525850A (ja) 2001-12-11
IL133098A (en) 2005-03-20
TW518236B (en) 2003-01-21
CA2290538C (en) 2007-01-02
IL133098A0 (en) 2001-03-19
ZA984127B (en) 1998-11-23
ID24332A (id) 2000-07-13

Similar Documents

Publication Publication Date Title
SE9701956D0 (sv) New composition of matter
TW200505483A (en) New medicament compositions based on anticholinergically-effective compounds and β-mimetics
PT937100E (pt) Nova forma polimorfica cristalina de propionato de fluticasona, um metodo para a sua producao e suas composicoes farmaceuticas
DE60121012D1 (de) Pharmazeutische zusammensetzung enthaltend resveratrol zur behandlung von entzündlichen erkrankungen der atemwege
ES8304797A1 (es) "procedimiento para la preparacion de nuevas formas orales de dipiridamol, en forma de granulados, pastillas o tabletas".
ES2152394T3 (es) Composicion para inhalacion que contiene granulos de lactosa.
FI20002215A0 (fi) Yhdistelmäpartikkelit
GB9425160D0 (en) Medicaments
CA2024916A1 (en) Respiratory disorder medicaments comprising salmeterol and fluticasone propionate
BE902185A (fr) Compositions pour les soins des voies respiratoires.
IL110681A (en) Pharmaceutical compositions containing flupirtine for the treatment of neurodegenerative diseases
DE3480053D1 (en) A kit or device and method for administering gangliosides and derivatives thereof of inhalation and pharmaceutical compositions suitable therefor
IL97796A0 (en) Pharmaceutical compositions containing n-alkylated 1,4-dihydropyridine-dicarboxylic acid esters,certain such compounds and their preparation
IL168308A (en) Compositions containing roflumilast and formoterol
UA60352C2 (uk) Синтетичні полісахариди та фармацевтична композиція, що їх містить
HUP0303450A2 (hu) Eljárás metoprololt tartalmazó mikrorészecskék előállítására és ezeket tartalmazó gyógyszerkészítmények
HK160795A (en) Bilobalide phospholipide complexes their applications and formulations containing them
CA2150183A1 (en) Pharmaceutical composition for the treatment of hemorrhoidal diseases
DE69918961D1 (de) Verbesserte inhalationspräparate
WO2002005801A3 (en) Compositions containing diacyltartaric salts of (e)-metanicotine
AR018376A1 (es) Composiciones farmaceuticas que se pueden dispersar de una manera espontanea y el uso de las mismas para la manufactura de un medicamento
FR2673105B1 (fr) Nouvelles compositions pharmaceutiques, notamment pour le traitement des colopathies fonctionnelles, et procedes de preparation de compositions et de medicaments, notamment pour le traitement de ces affections.
UA88284C2 (ru) Твердая лекарственная форма, которая содержит действующее вещество из группы ингибиторов обратного захвата моноаминовых нейротрансмиттеров с 2,3-двухзамещенным тропановым скелетом, способ ее получения и применения
DK0950053T3 (da) Hidtil ukendte benzoylalkyl.1,2,3,6-tetrahydropyridinderivater
CO4340686A1 (es) Compuestos farmaceuticos de 6-(2-imidazolinilamino) quinoxa- lina, utiles en el tratamiento y la prevencion de desorde- nes respiratorios y de desordenes intestinales